ABT 122

Drug Profile

ABT 122

Alternative Names: ABT-122

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Abbott Laboratories
  • Developer AbbVie
  • Class Antirheumatics; Immunoglobulins; Monoclonal antibodies
  • Mechanism of Action Interleukin-17 inhibitors; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Rheumatoid arthritis

Highest Development Phases

  • Phase II Psoriatic arthritis; Rheumatoid arthritis

Most Recent Events

  • 13 Jul 2016 AbbVie completes a phase II trial for Psoriatic arthritis (Treatment-expirienced) in USA, Australia, Bulgaria, Czech Republic, France, Germany, Hungary, Latvia, New Zealand, Poland, Romania and Spain (NCT02349451)
  • 16 Jun 2016 AbbVie terminates a phase II extension trial for Psoriatic arthritis in Australia, Bulgaria, Czech Republic, France, Germany, Hungary, Italy, Latvia, New Zealand, Poland, Romania, Spain (NCT02429895)
  • 31 May 2016 AbbVie completes a phase II extension trial for Rheumatoid arthritis (Combination therapy, Treatment-experienced) in Australia, Bulgaria, Czech Republic, Germany, Hungary, New Zealand, Poland and Romania (NCT02433340)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top